China Approves Use of Roche Drug in Battle Against Coronavirus Complications

by swisschambei in Engineering / Manufacturing

China has approved the use of Swiss drugmaker Roche’s anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide. China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients. Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases. China’s National Health Commission said in treatment guidelines published online that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Your Swiss Business Platform in China

SwissCham China has roughly 600 company members. Our Chamber maintains a strong relationship with the Embassy of Switzerland, Swiss Global Enterprise, Swissnex and Switzerland Tourism. As the representative of the Swiss companies established in China, our goal is to help you to increase your business and visibility, especially amongst the Sino-Swiss business community.

Become A Member

Sign Up For Our Newsletter

  • This field is for validation purposes and should be left unchanged.
June 4, 2021
Published By swisstrade.com in Bilateral Relations
June 3, 2021
Published By prnewswire.com in Business
May 28, 2021
Published By chinadaily.com.cn in Engineering / Manufacturing
May 20, 2021
Published By globaltimes.cn in Bilateral Relations
May 18, 2021
Published By globaltimes.cn in Culture & Society